GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XBUL:EVT) » Definitions » Capital Expenditure

Evotec SE (XBUL:EVT) Capital Expenditure : лв-359.42 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Evotec SE's cash flow for capital expenditures for the three months ended in Sep. 2024 was лв-60 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was лв-359.42 Mil.

Evotec SE Capital Expenditure Historical Data

The historical data trend for Evotec SE's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Capital Expenditure Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.51 -229.54 -255.96 -365.87 -448.59

Evotec SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -93.34 -137.16 -81.09 -81.28 -59.89

Evotec SE Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was лв-359.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XBUL:EVT) » Definitions » Capital Expenditure
Comparable Companies
XTER:B8FK ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS SZSE:000538 NBIX BOM:543904 BOM:500124 NSE:TORNTPHARM HKSE:03692 TSE:4507 BOM:500257 CTLT
Traded in Other Exchanges
EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Austria
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Website
https://www.evotec.com
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.